Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Factors Associated with Recurrent Coronary Events Among Patients with Cardiovascular Disease
Pharmacotherapy, 08/03/09
McConnell KJ et al. – These results support use of a statin at moderate–to–high doses as the basis of therapy for secondary coronary event prevention. The LDL:HDL ratio may help determine the degree of LDL lowering beyond traditional treatment goals.
Related Articles
Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study
Arthritis & Rheumatism, 11/05/09
Relevance Score: 71%
Chronic renal insufficiency, cardiovascular disease and mortality in women: a causal relationship or coincidence?
Women's Health, 11/02/09
Relevance Score: 70%
Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden
Rheumatology, 10/30/09
Relevance Score: 70%
Frequency of migraine and the risk of cardiovascular disease for women: limited evidence of an association
Women's Health, 10/30/09
Relevance Score: 69%
Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the Nurses Health Study
Arthritis Care and Research, 10/01/09
Relevance Score: 69%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Valsartan and aliskiren (Valturna): Combination of an angiotensin receptor blocker with direct renin inhibitor approved for the treatment of hypertension
Formulary , 12/02/09
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Vascular Health and Risk Management, 12/01/09
Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
Expert Opinion on Investigational Drugs, 12/01/09
Sponsor
Article Search
Sponsor


See Latest Articles


